{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 1.6216176, "regularMarketPrice": 18.8, "exchange": "FRA", "shortName": "SOSEI GROUP CORP", "longName": "Sosei Group Corporation", "messageBoardId": "finmb_1266465", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683872766, "trailingAnnualDividendRate": 0.0, "trailingPE": 626.6666, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 0.03, "sharesOutstanding": 81923000, "bookValue": 707.201, "fiftyDayAverage": 16.612, "fiftyDayAverageChange": 2.1879997, "fiftyDayAverageChangePercent": 0.131712, "twoHundredDayAverage": 14.4545, "twoHundredDayAverageChange": 4.345499, "twoHundredDayAverageChangePercent": 0.30063295, "marketCap": 1588389376, "priceToBook": 0.026583672, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1549609200000, "priceHint": 2, "regularMarketChange": 0.29999924, "regularMarketDayHigh": 18.8, "regularMarketDayRange": "18.8 - 18.8", "regularMarketDayLow": 18.8, "regularMarketVolume": 33, "regularMarketPreviousClose": 18.5, "bid": 18.8, "ask": 19.8, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "JPY", "regularMarketOpen": 18.8, "averageDailyVolume3Month": 3, "averageDailyVolume10Day": 3, "fiftyTwoWeekLowChange": 11.749999, "fiftyTwoWeekLowChangePercent": 1.6666665, "fiftyTwoWeekRange": "7.05 - 19.6", "fiftyTwoWeekHighChange": -0.80000114, "fiftyTwoWeekHighChangePercent": -0.040816385, "fiftyTwoWeekLow": 7.05, "fiftyTwoWeekHigh": 19.6, "symbol": "JSS.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "PMO Hanzomon", "address2": "11th Floor 2-1 Kojimachi Chiyoda-ku", "city": "Tokyo", "zip": "102-0083", "country": "Japan", "phone": "81 3 5210 3290", "website": "https://soseiheptares.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Mr. Shinichi  Tamura", "age": 73, "title": "Founder & Chairman", "yearBorn": 1949, "fiscalYear": 2021, "totalPay": {"raw": 2423920, "fmt": "2.42M", "longFmt": "2,423,920"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Cargill", "age": 38, "title": "Representative Exec. Officer, Pres, CEO & Director", "yearBorn": 1984, "fiscalYear": 2021, "totalPay": {"raw": 1707090, "fmt": "1.71M", "longFmt": "1,707,090"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Hironoshin  Nomura", "title": "Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kieran  Johnson F.C.A.", "title": "Exec. Officer, VP & Chief Accounting Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Miles  Congreve", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kazuhiko  Yoshizumi", "age": 68, "title": "Exec. Officer, VP & Chief Compliance Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Shinichiro  Nishishita", "title": "VP of Investor Relations & Head of Regulatory Disclosures", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Stacey  Southall", "title": "Associate Director & Head of Biophysics", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Candelle  Chong", "title": "Exec. Officer, Exec. VP & Chief of Staff", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matt  Barnes", "title": "Head of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}